Exelon Corp

EXC remains in a medium-term mean-reversion setup following extreme oversold conditions within a broader Stage 4 decline. The medium-term bias is bullish under mean-reversion eligibility, but short-term price action remains below declining EMAs and has been rejected at resistance, warranting deferred entry. A firm acceptance above the 9–20 EMA cluster or support around the 43.6–44.1 zone would improve execution readiness, while a breakdown below this support range would invalidate the bounce thesis.

• ↑Q2 adjusted EPS of $0.43 per share reaffirms full-year $2.81–$2.91 guidance.
• ↑$41.3 B capex plan through 2029 targets a 5–7% growth in transmission infrastructure.
• ↓Negative growth and revision trends suggest faltering top-line momentum.